TORONTO, Nov. 18,
2022 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or
the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMXC), the global leader in
medical cannabis throughout Latin
America and Europe, today
announces that it will host a Conference Call on November 30, 2022 at 11:00
a.m. eastern time to discuss its results for the third
quarter ended September 30, 2022. The
Company will press release its financial results prior to the
Conference Call. These filings will be available for review on the
Company's SEDAR profile at www.sedar.com
Khiron invites individual and institutional investors, as well
as advisors and analysts, to attend the Company's Third Quarter
2022 Conference Call, followed by a Q&A session.
Webcast Details:
DATE: Wednesday, November 30,
2022
TIME: 11:00am ET
PRESENTERS: Alvaro Torres, Khiron
Chief Executive Officer and Director, Helen
Bellwood, Khiron Chief Financial Officer, and Franziska
Katterbach, President of Khiron Europe.
FORMAT: Live 45 minute presentation & Q&A session
REGISTER LINK:
https://us06web.zoom.us/webinar/register/WN_nB0mQsxmR2SgKJCnHlhL9Q
About Khiron Life Sciences
Corp.
Khiron is a leading global medical cannabis company with core
operations in Latin America and
Europe. Leveraging wholly-owned
medical health clinics and proprietary telemedicine platforms,
Khiron combines a patient-oriented approach, physician education
programs, scientific expertise, product innovation, and focus on
creating access to drive prescriptions and brand loyalty with
patients worldwide. The Company has a sales presence in
Colombia, Germany, UK, Peru, and Brazil and is positioned to commence sales in
Mexico. The Company is led by
Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca
Linkedin
https://www.linkedin.com/company/khiron-life-sciences-corp/
Forward-Looking
Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/khiron-to-host-third-quarter-2022-conference-call-on-november-30-2022-301681724.html
SOURCE Khiron Life Sciences Corp.